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https://doi.org/10.1016/j.celrep.2020.107816SUMMARYInhibition of anti-apoptotic proteins BCL-2 and MCL-1 to release pro-apoptotic protein BIM and reactivate
cell death could potentially be an efficient strategy for the treatment of leukemia. Here, we show that a
lncRNA, MORRBID, a selective transcriptional repressor of BIM, is overexpressed in human acute myeloid
leukemia (AML), which is associated with poor overall survival. In both human and animal models,MORRBID
hyperactivation correlates with two recurrent AML drivers, TET2 and FLT3ITD. Mice with individual mutations
of Tet2 or Flt3ITD develop features of chronic myelomonocytic leukemia (CMML) and myeloproliferative
neoplasm (MPN), respectively, and combined presence results in AML.We observe increased levels ofMorr-
bid in murine models of CMML, MPN, and AML. Functionally, loss of Morrbid in these models induces
increased expression of Bim and cell death in immature and mature myeloid cells, which results in reduced
infiltration of leukemic cells in tissues and prolongs the survival of AML mice.INTRODUCTION
One of the well-recognized hallmarks of cancer, including acute
myeloid leukemia (AML), is its capability to evade cell death,
which may also act as an underlying mechanism of drug resis-
tance and/or tumor relapse in certain cancer therapies (Hanahan
andWeinberg, 2011; McBride et al., 2019; Merino et al., 2018). It
has been almost 30 years since the identification of BCL-2 and
its family members in regulating cell apoptosis (anti-apoptosis:
BCL-2, BCL-lnctnXL, and MCL-1; pro-apoptosis: BIM, BID,
BAX, and BAK). The anti-apoptosis proteins of the BCL-2 family
execute their function by sequestering pro-apoptosis proteins
and preventing the creation of pores in the mitochondrial outer
membrane via protein-protein interactions (Ashkenazi et al.,
2017; Huang et al., 2019; Yang et al., 2019). Repressing the
expression of anti-apoptosis protein via gene silencing or inhib-
iting such protein-protein interaction via BH3mimetics are there-
fore emerging as novel targeting treatments for cancer, including
several hematological malignancies in which BCL-2 and/or
MCL-1 are aberrantly activated in leukemic stem cells (LSCs)
or leukemic blasts. Indeed, venetoclax (ABT-199), an oral BCL-
2 inhibitor, has been approved for the treatment of chronic lym-
phocytic leukemia and elderly patients with AML (DiNardo et al.,This is an open access article under the CC BY-N2019). Similarly, inhibition of MCL-1 via S64315 or AMG-176 as a
single-agent therapy or in combination with BCL-2 inhibitor and
other drugs is in clinical trials for AML treatment (Anstee et al.,
2019; Caenepeel et al., 2018; Ramsey et al., 2018; Teh et al.,
2018). Although BCL-2 itself is an important player in tumorigen-
esis and represents an important therapeutic target, in vivo stim-
ulation of the expression of pro-apoptosis proteins in AML treat-
ment (e.g., BIM) has not been studied in preclinical models
(Shukla et al., 2017).
AML is a genetically and cellularly heterogenous clonal blood
cancer caused by driver mutations that are able to transform he-
matopoietic stem cells (HSCs) to LSCs. The most prevailing ones
include acute myelomonocytic leukemia (French-American-
British [FAB] classification, M4) and acute monocytic leukemia
(M5), where both mature myeloid cells and progenitors are
leukemic and redundant. The recurrent mutations in M4 and M5
AML include genes encoding components of the signaling
pathway and epigenetic regulations, such as the gain-of-function
mutation FLT3ITD/+ and the loss-of-function mutation TET2+/.
Indeed, using murine models, recent studies suggest that muta-
tions in Tet2 define a preleukemic condition in HSCs and may
induce clonal hematopoiesis of indeterminate potential (CHIP),





(legend on next page)






OPEN ACCESS2019). Acquisition of additional mutations such as Flt3ITD/+ in pre-
leukemic cells bearing loss of Tet2 results in the development of
full-blown AML (Shih et al., 2015). Furthermore, the Tet2/;
Flt3ITD/ITD model of AML, the preleukemic model bearing Tet2
loss, and a murine model expressing a knockin allele of Flt3ITD
manifest several cardinal features of human AML, chronic myelo-
monocytic leukemia (CMML), and myeloproliferative neoplasm
(MPN), respectively (Chu et al., 2012; Moran-Crusio et al., 2011;
Shih et al., 2015). Use of these clinically relevant models of
myeloid neoplasm allow for validation of targets that are likely to
provide best insight into human leukemia and its genetic drivers.
We have recently shown that the evolutionarily conserved
novel long non-coding RNA (lncRNA) Morrbid is specifically ex-
pressed in myeloid cells and uniquely represses the expression
of the pro-apoptotic gene Bim via DNA loop in cis to regulate
the lifespan of myeloid cells (Kotzin et al., 2016). Morrbid/
mice manifest inefficient production of innate immune cells
(50% of wild-type [WT] levels) but have normal activity and life-
span (Kotzin et al., 2016). SinceMorrbid is specifically expressed
in myeloid cells (i.e., neutrophils [NEs], monocytes [MOs], and
eosinophils), but not in other cell types under physiologic condi-
tions, the uniqueness of its expression pattern and function of-
fers a great advantage and opportunity to test if it is required
for the onset and progression of myeloid-related diseases,
including various myeloid neoplasms. In the present study, we
have characterized the role of lncRNA MORRBID/Morrbid and
its target, BIM, in regulating the survival of preleukemic and
leukemic cells.
RESULTS AND DISCUSSION
Role of Morrbid in Murine Models of CMML and MPN
Our recent study has defined the role of Morrbid in inflammation
and Tet2-mutation induced aberrant emergency granulopoiesis
and clonal hematopoiesis (Cai et al., 2018). We here first
compared the role of Morrbid in driving Tet2-mutation-induced
CMML and Flt3ITD-mutation-induced MPN over an adequate life-
time, since CMML is a chronic disease in the elderly population
(Figure 1A; Chu et al., 2012; Lee et al., 2007; Mead et al., 2013;
Mead et al., 2017; Moran-Crusio et al., 2011). We generated
Tet2/; Morrbid/ double homozygous mice along with all the
controls. A large cohort of thesemicewas allowed to age and sub-
sequently analyzed for peripheral blood (PB) changes. Consistent
with previous studies, as seen in Figure 1B, although the average
count of white blood cells (WBCs) in aged Tet2/ mice is higher
than that in WT controls, the counts of WBCs in each Tet2/ in-
dividual mouse are highly variable relative to controls, suggesting
that the onset and penetration of the CMML-like disease in eachFigure 1. Morrbid’s Role in Tet2-Mutation-Induced CMML and Flt3ITD-
(A) Schematic for generating Tet2/; Morrbid/ (TM) and Flt3ITD/ITD; Morrbid/
(B andC) Examination of peripheral blood (PB), bonemarrow (BM), and spleen in th
(age, 12 months).
(D and E) Examination of PB, BM, and spleen in the four experimental groups: W
(B and D) Plots of PB cell counts (upper panel) and representative profiles of flow
panel).
(C and, E) quantification of BM cellullarity and spleen weight.
n = 4–19. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.individual is different in the large cohort. However, the increase
in average value of WBC counts observed in Tet2 deficient mice
was normalized and not highly variable in Tet2/; Morrbid/
mice (Figure 1B). Importantly, a similar and significant reversal in
the increase in absolute number of NEs and MOs was observed
in Tet2/; Morrbid/ mice compared to Tet2/ mice. Likewise,
the increase in the frequency of NEs andMOs observed in Tet2/
mice was also rescued in the absence of Morrbid, along with the
decrease in bone marrow (BM) cellularity and spleen weight (Fig-
ure 1B). Overall, while the percentages of NEs and MOs in
Tet2/; Morrbid/ mice remained higher than WT controls,
they were significantly lower than that observed in Tet2/ mice
(Figure 1B). In contrast, no improvement in red blood cell (RBC)
counts was observed in Tet2/; Morrbid/ mice, suggesting
that Morrbid does not impact the reduction in RBCs observed in
aged Tet2/ mice (Figure 1B).
Compared to Flt3ITD/+ mice, Flt3ITD/ITD mice develop an early
onset and full penetration of MPN-like phenotype via activation
of STAT signaling, which eventually results in the activation of
anti-apoptotic proteins BCL-2 orMCL-1 (Chu et al., 2012; Kikush-
ige et al., 2008; Mead et al., 2013, 2017; Naganna et al., 2019).
These mice develop several cardinal features of human MPN-
like disease, including enhanced NE andMO counts, splenomeg-
aly, and hyperceullular BM (Figures 1D and 1E). To determine the
extent to which these changes are regulated byMorrbid-induced
Bim repression, we generated mice lackingMorrbid and express-
ing Flt3ITD/ITD (Flt3ITD/ITD; Morrbid/). Similar to the results seen in
the Tet2-deficiency-driven CMML model lacking Morrbid, we
observed that loss of Morrbid in the setting of Flt3ITD/ITD expres-
sion rescued the abnormal phenotypes observed in Flt3ITD/ITD,
including high NE and MO counts in PB (Figure 1D). Interestingly,
while RBC and spleen size were not significantly corrected in the
Flt3ITD/ITD mice lackingMorrbid, BM hypercellularity is completely
rescued (Figures 1D and 1E). Taken together, these results sug-
gest that Morrbid loss is able to partially correct the CMML and
MPN phenotype in the setting of two distinct AML driver muta-
tions, Tet2 and Flt3ITD.
Role of MORRBID/Morrbid in Human and Murine AML
Wenext aimed to extend these findings to assess the role ofMorr-
bid in an aggressive form of AML driven by a combination of loss
of Tet2 and expression of Flt3ITD/ITD (i.e., Tet2/; Flt3ITD/ITD). We
first mined the human AML gene expression database (unclassi-
fied, various subtypes included) aswell as primary patient-derived
AML samples to determine the contribution of MORRBID in hu-
man AML. As seen in Figure 2A, the presence of MORRBID is
significantly higher in unclassified AML patients compared to
normal control individuals. Furthermore, we also observed that aInduced MPN
(FM) compound mutant mice along with controls.
e four experimental groups: wild type (WT), Tet2/ (T),Morrbid/ (M), and TM
T, Flt3ITD/ITD (F), Morrbid/ (M), and FM (age, 2 months).
cytometry of mature myeloid cells (Mac1+) and B cells (CD19+) from BM (lower
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Figure 2. Highly Conserved Mammalian lncRNA MORRBID/Morrbid Is Hyperactivated in Human and Murine Models of AML
(A) Boxplot showing the expression levels of theMORRBID transcript in 150 normal whole-blood samples from the Genotype-Tissue Expression (GTEx) project
compared against its expression in 175 AML samples from TCGA project. *p < 2.2e16, Wilcoxon test.
(B) Boxplot showing the expression levels ofMORRBID in BM samples of AML patients with TET2mutation (left) or WT TET2 (right) from TCGA gene expression
data. y axis represents the log-normalized gene expression level. p = 0.048, Mann-Whitney test.
(C) Overall survival of TET2 mutated patients with high/low expression of MORRBID. A significant integrative effect of high expression MORRBID and TET2
mutation in determining patient’s overall survival was observed compared to low expression of MORRBID. *p = 0.047.
(D) Increased expression ofMORRBID in AML cells with FLT3ITD mutation (FLT3ITD(+)) compared to AML cells without FLT3ITD mutation (FLT3ITD(-)). Mononuclear
cells derived from AML patients negative for FLT3ITD (left) or positive for FLT3ITD (right) were subjected to qRT-PCR for MORRBID expression. n = 29 FLT3ITD(+)
AML and 63 FLT3ITD() AML. **p < 0.01, Student’s t test.
(E) Scatterplot of normalized gene expression level showing the top 1.1%percentile ofMORRBID expression level among 20,134 genes and lncRNAs in nine bulk
human AML stem cell samples.
(F) Murine model of AML used in the present study. Flt3ITD/ITD mice (F) were bred with Tet2/ mice (T) to generate Tet2/; Flt3ITD/ITD mice (TF).
(G) Representative apoptosis profiles in myeloid cells (Mac1+) of WT and TF mice determined by Annexin-V staining (n = 4).
(H) Expression of Morrbid and Bim in Lin cells analyzed by qRT-PCR. **p < 0.01; ***p < 0.001.







Figure 3. Genetic Loss of Morrbid in the Context of Tet2/;Flt3ITD/ITD Mice Rescues Myeloid Cell Abnormalities
(A) A schematic describing various experimental approaches utilized to study the role of Morrbid in driving AML. TF mice were bred with Morrbid/ mice to
generate Tet2/; Flt3ITD/ITD; Morrbid/mice, indicated as TFM. The impact ofMorrbid deficiency was analyzed in the original TFmice (primary mice) by utilizing
BMcells derived from thesemice and transplanting them intoWT recipients and conducting competitive transplant experiments utilizing donors from TF and TFM
mice along with normal WT competitors.
(B) Examination of PB parameters in the four experimental groups: WT, TF, TFM, andM. Shown are WBC, NE, RBC, and PLT counts as well as the frequency of
NEs in various experimental groups. NE, neutrophil. PLT, platelet. RBC, red blood cell. WBC, white blood cell.
(C) Representative flow cytometry plots from PB of the four genotypes. Cells were stained with a combination of antibodies recognizing CD19 (B cells), Mac1
(myeloid cells), CD3 (T cells), and Gr1 (myeloid cells) markers. The percentage of various subsets are indicated in each quadrant in red.
(D) Lung histology from the four experimental groups. Infiltration of leukemic cells in the lung of TFM mice was reduced compared to TF mice.
n = 4–10; **p < 0.01; ****p < 0.0001.
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OPEN ACCESSsubset of AML patients bearing TET2mutations show significantly
higher expression ofMORRBID (p = 0.048 by Mann-Whitney test)
and worse overall survival compared to AML patients lacking
TET2 mutations (p = 0.047 by log-rank test) from The Cancer
Genome Atlas (TCGA) data (Figures 2B and 2C). Likewise, in
AML samples collected from our own institution, AML patients
with FLT3ITD mutations manifest 3-fold higher expression of
MORRBID compared to AML patients without FLT3ITD mutations
(Figure 2D). Analysis on another independent dataset with expres-
sion of 20,134 genes, including lncRNAs, further confirmed that
MORRBID is expressed in human leukemic stem cell (LSC) sam-
ples and its expression level is among top 1.1% percentile (Fig-
ure 2E). Taken together, these results suggest that hyperactivation
of MORRBID is highly associated with TET2 and FLT3ITD muta-
tions in human AML (Figures 2B–2D) or even unclassified AML
(Figures 2A and 2E).
To evaluate the potential functional significance ofMORRBID in
AML,wenextutilizedamurinemodelofAML inducedby the lossof
Tet2 and expression of Flt3ITD (Tet2/;Flt3ITD/ITD, TF) (Figure 2F).
Consistent with a previous report (Shih et al., 2015), TFmiceman-
ifest full penetration of abnormalities and high percentage of
myeloid cells in the circulation (percentage of Mac1+; 21.9% in
WT versus 59.6% in TF), while B cell development is repressed
(percentageofCD19+: 47.6% inWTversus1.76% inTF). Addition-
ally, flow cytometry analysis with apoptosis marker Annexin-V
showed thatMac1+ cells inTFmice are resistant to cell death (per-
centage of Annexin-V+: 27.3% in WT versus 10.1% in TF) (Fig-
ure 2G). Importantly, expression ofMorrbid is significantly greater
in BM Lin cells derived from TFmice compared toWTmice, and
expression of the gene encoding pro-apoptotic protein Bim (also
known as Bcl2l11) is significantly reduced in TF Lin cells (Fig-
ure 2H). Given these findings, we hypothesized that TF model of
AML is suitable to study the functional consequences of Bim in-
duction in the absence of Morrbid. We therefore generated mu-
tants of TF lacking Morrbid (Tet2/;Flt3ITD/ITD;Morrbid/,TFM)
and all the necessary controls (Figure 3A). We conducted three
different experiments to define the functional requirement ofMorr-
bid in induction and prevention of AML driven by TF in (1) primary
TFandTFMmice, (2) BM-derived recipient animalswithTForTFM
donors, and (3) BM-reconstituted recipients with competitor do-
nors (BoyJ WT donor’s versus TF or TFM donors) (Figures 3A,
4A, and 5A). In all three scenarios, TFM mice or recipient mice
with TFM donors manifest reduced WBC, NE and MO counts
compared to controls (Figures 3B and 4C). Similar to our findings
described earlier in TM and FM mutant mice (Figures 1 and 2),
loss of Morrbid was unable to rescue the defects associated
with RBCs in TFM mice (Figure 3B). In contrast, loss of Morrbid
in TF-driven AML, reduced the leukemic cell percentage in PB
and mitigated their infiltration into the lung of TFM mice (FiguresFigure 4. Increased Survival of Mice Transplanted with TFM Donor Ce
(A) A schematic of recipient mice undergoing primary and secondary transplanta
(B) Enhanced survival of recipient mice transplanted with TFM donor cells in sec
(C and D) Loss ofMorrbid in the setting of TF cells rescuesWBC and NE counts as
PB. D, samples from BM and spleen.
(E)Morrbid deficiency in the context of TF cells rescues the absolute number of Lin
myeloid progenitors (CMPs) to near-WT levels.
n = 4–10; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.3C and 3D). Importantly, loss of Morrbid in the setting of TF cells
extended the survival of BM-reconstituted animals with TF donors
relative to controls in secondary transplant recipients (Figure 4B).
Furthermore, while not changing the differentiation abnormalities
in Lin-Sca1+-cKit+ cells (LSKs), common myeloid progenitors
(CMPs), and granulocyte-monocyte progenitors (GMPs), loss of
Morrbid reduced the BM cellularity and absolute number of pro-
genitor cells, including Lin,LSK, GMP, and CMP cells, in the BM
of recipient mice transplanted with TFM donor cells compared to
controls (Figures 4D and 4E). In experiments involving competitive
transplantation, loss ofMorrbid in the setting of TF also mitigated
the clonal expansion observed using TF cells in PB and BM (Fig-
ures 5B, 5C, and 5E). Loss of Morrbid in the setting of TF was
also slightly but significantly able to increase the portion of B cells
(Figure 5G). Additionally, the increase in spleen size associated
with TF donors was completely rescued when cells were trans-
planted using TFM donors under a competitive setting using
BoyJcells ascompetitors (Figure5F), further supporting the notion
that loss of Morrbid represents a novel therapeutic strategy for
AML treatment.
Given the significant correction of phenotype observed in TFM
mice, we next sought to determine the extent to which loss of
Morrbid impacts apoptosis in various compartments of the BM,
including Mac1+ cells, myeloid progenitor (MP) cells (Lin-cKit+-
Sca1), and LSK cells. As seen in Figure 6A, the reduction in
apoptosis observed in Mac1+, MP, and LSK cells associated
with TFmicewas partially reversed in the TFMmice. Consistently,
an increase in the expression of Bim in TFM cells was determined
by both qRT-PCR and mean fluorescence intensity (MFI) assays
(Figures 6B and 6C). Taken together, these results suggest that
targeting Morrbid induces apoptosis in leukemic cells. Although
the mechanism of transcriptional repression of Bim by Morrbid
via DNA loop in cis was initially addressed in our previous studies
(Kotzin et al., 2016), future studies are required to assess the
extent to which Morrbid itself, rather than the act of its transcrip-
tion, may be the primary mediator of Bim regulation.
To evaluate if there is any substantial functional difference be-
tween BCL-2/MCL-1 inhibition andMorrbid targeting, we treated
TFmice with single-agent ABT-199 (a selective inhibitor of BCL-
2), S63845 (a selective inhibitor of MCL-1), or 5-azacytidine (an
effective drug for TET2-mutation-related myelodysplastic syn-
dromes [MDS]) or with various combinations (Figure 7A; DiNardo
et al., 2019; Pollyea et al., 2018). Although a high dose of ABT-
199 and 5-azacytidine is toxic to the animal (data not shown),
TF mice are resistant to treatment with any of the single agents
at low dose or with a combination treatment of low dose ABT-
199 and S63845 (Figures 7A and 7B). A drug regimen with a
low dose of all three drugs (ABT-199 + S63845 + 5-azacytidine)
is sufficient to reduce WBCs, NEs, and MOs in TF mice afterlls Compared to TF Cells
tion using BM derived donor cells from the four genotypes.
ondary recipients compared to TF donors.
well as NE frequency and BM cellularity, but not spleen size. (C) Samples from
 cells, LSK cells, granulocyte-macrophage progenitors (GMPs), and common








Figure 5. Growth Advantage of TF Cells Was Mitigated When Morrbid Is Depleted
(A) Donor cells from TF or TFMmice along with WT andMorrbid/ controls were mixed with BoyJ cells in identical cell number (0.53 106 versus 0.53 106) for a
competitive transplantation assay.
(B) Chimerism analysis of PB, BM, and spleen samples from chimeric mice at the indicated time points post transplantation.
(legend continued on next page)






Figure 6. Morrbid Loss Induces Increased Expression of Bim and Apoptosis in Leukemic Cells, Including Mature Myeloid Cells (Mac1+),
Myeloid Progenitor Cells (LinSca-1cKit+), and LSK Cells
(A) Level of apoptosis as determined by Annexin-V staining.
(B) Expression of Bim in Lin cells as analyzed by qRT-PCR.
(C) Expression of Bim in myeloid cells and LSK cells as analyzed by intracellular staining of Bim and quantified by mean fluorescence intensity (MFI).
n = 4; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
Article
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OPEN ACCESSthree cycles of treatment (Figure 7B). However, this treatment
failed to improve RBC counts (Figure 7B). Although the ratio of
mature myeloid cells and B cells was slightly altered in the PB,
BM, and spleen (Figure 7C), analysis of hematopoiesis on
hematopoietic progenitors such as LSKs, CMPs and GMPs
in the drug treated TF mice showed that this treatment failed
to change the differentiation abnormalities associated with
TF mice in the BM and spleen (data not shown). Future experi-
ments are required to compare the impact of Bcl-2 repression
via ABT-199 in TFM mice and TF mice to assess whether direct
repression of Bcl-2 in TFM mice further improves the AML
phenotype.
In summary, we have defined a critical role for a novel myeloid
regulatorMorrbid in a spectrum of myeloid neoplasms, including
CMML, MPN, and AML. Our results show that Morrbid is a
myeloid-specific cell survival regulator not only in physiologic
conditions but also in leukemic conditions.(C and E) Representative chimerism profiles in BM (C) and spleen samples (E).
(D and F) BM cellularity (D) and spleen weight (F) were examined at 6 months po
(G) In chimeric mice, the portion of B cells is partially corrected in recipient mice
Student’s t test (n = 4–10); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
MICE
All the animal experiments were approved and maintained by Laboratory Animal Resource Center at Indiana University School of
Medicine. C57/B6mice (CD45.2+) were procured from IUSM core facility and used as wild-type controls. For transplantation studies,
congenic BoyJ mice (CD45.1+) or F1 mice (CD45.1+CD45.2+) were procured from IUSM core facility and used as wild-type controls.
CMMLmodel mice (Tet2/), MPNmodel mice (Flt3ITD/+) andMorrbid deficient mice (Morrbid/) have been described (Kotzin et al.,
2016; Lee et al., 2007; Li et al., 2011) andwere bred for generating the compoundmutants. Agematchedmice (bothmale and female)
were analyzed: for CMML analysis, mouse sample were collected at old age (12 month old); for MPN analysis, mouse sample were
collected at young age (2month old); for AML analysis, mouse sample were collected at large-range of age as indicated (26month
old or 26 month post the transplantation).
Human Blood Samples
Peripheral blood (PB) samples of human AML patients (both male and female) enrolled in our affiliated hospital were obtained from
our blood bank with approved protocol.
METHOD DETAILS
Mouse Experimental Procedures
Analysis procedures involving mouse experiments (i.e., flow cytometry strategies and Annexin-V gating and intracellular staining for
anti-Bim) have been in described in detail in our recent study (Cai et al., 2018).
qRT-PCR analysis of MORRBID using human AML blood samples
Peripheral blood of AML patients enrolled in our affiliated hospitals were sorted for monocytes and then analyzed by qRT-PCR for
determining the association betweenMORRBID expression and FLT3ITDmutation. Expression ofHPRTwas used as internal control.
Genomic DNA from blood samples was also purified and FLT3ITD mutation was determined by PCR genotyping.
Bioinformatic analysis of MORRBID and survival burden in human AML
To identify which lncRNAs potentially associated with AML, we downloaded raw RNA-seq data for 175 AML samples from TCGA,
along with the pertaining patient clinical data. The downloaded data was aligned to the human reference genome (GRCh38) usinge2 Cell Reports 31, 107816, June 23, 2020
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OPEN ACCESSHISAT2 and transcript abundance was computed using StringTie. Microarray data of the TCGA AML samples were also downloaded
and analyzed. Genome scale survival analysis was performed over the AML expression and clinical data obtained from TCGA, using
survival R package (https://github.com/therneau/survival), to obtain the survival statistics for all human lncRNAs obtained from Gen-
code v24. The top 20 (sorted ascending by FDR) lncRNAs including MORRBID were extracted for further analysis. Simultaneously,
we downloaded 150 normal whole blood gene abundance data from the GTEx project to observe and compare lncRNA expression
levels across AML and normal whole blood. Log-rank test was used to test the prognostic association of MORRBID in the AML pa-
tients with TET2mutations. 17 TET2mutated samples with both gene expression andmutation were analyzed. High and low expres-
sion level ofMORRBIDwas determined by higher than 65% quantile and lower than 35% quantile of its expression level. To demon-
strate the significant expression of MORRBID in human AML leukemic stem cells, we retrieved the dataset GSE17054 from NCBI
GEO database (Majeti et al., 2009), which contains 9 samples of bulk leukemic stem cell (LSC) samples collected from AML patients.
We compared the averaged expression ofMORRBID versus other genes in the 9 AML LSC samples. Our analysis suggestsMORR-
BID is among the top 1.1% expressed genes and lncRNA in all the measured probes.
QUANTIFICATION AND STATISTICAL ANALYSIS
All experimental procedures on mice were run in parallel with proper controls (sex and age matched littermate controls when
possible) for observing experiment variabilities. Analysis of grouped data was not blinded and no sampleswere excluded. If not spec-
ified, P value was calculated using an unpaired t test for comparing means of two groups (GraphPad Prism 6.0). Error bars indicate
the standard error of mean (s.e.m.).Cell Reports 31, 107816, June 23, 2020 e3
